BACKGROUND: Hepatitis B virus (HBV) infection is common with major clinical consequences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which approximates the rates from their countries of origin. Similarly, HBV is the most important cause of cirrhosis, hepatocellular carcinoma (HCC) and liver related deaths in HBsAg positive Asians worldwide.
AIM: To generate recommendations for the management of Asian Americans infected with HBV.
METHODS: These guidelines are based on relevant data derived from medical reports on HBV from Asian countries as well as from studies in the HBsAg positive Asian Americans. The guidelines herein differ from other recommendations in the treatment of both HBeAg positive and negative chronic hepatitis B (CHB), in the approach to HCC surveillance, and in the management of HBV in pregnant women.
RESULTS: Asian American patients, HBeAg positive or negative, with HBV DNA levels >2000 IU/mL (>10
CONCLUSIONS: Application of the recommendations made based on a review of the relevant literature and the opinion of a panel of Asian American physicians with expertise in HBV treatment will inform physicians and improve patient outcomes.
Recommended CitationTong, M. J.; Pan, C. Q.; Han, S.-H. B.; Lu, D. S.-K.; Raman, S.; Hu, K.-Q.; Lim, J. K.; Hann, H.W.; and Min, A. D., "An expert consensus for the management of chronic hepatitis B in Asian Americans." (2018). Division of Gastroenterology and Hepatology Faculty Papers. Paper 56.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.